Literature DB >> 21178355

Effect of psychiatric severity on the outcome of methadone maintenance treatment.

Pier Paolo Pani1, Icro Maremmani, Matteo Pacini, Francesco Lamanna, Angelo G I Maremmani, Liliana Dell'osso.   

Abstract

While psychiatric comorbidity has been shown to produce a negative impact on the outcome of opioid use disorders, longitudinal studies carried out in the context of methadone maintenance treatment programs (MMTP) to evaluate outcomes strictly linked to methadone efficacy have not demonstrated a similar negative influence. To verify whether results obtained considering psychopathology in terms of formal psychiatric diagnoses were replicated when assessing psychopathology in terms of global psychiatric severity, a retrospective cohort study was designed. 259 patients commencing methadone maintenance treatment were divided into two groups on the basis of SCL-90 severity score and compared for retention in treatment, toxicological urine test results and psychological/psychiatric status throughout a one year period of observation. The results of the study suggest that patients in MMTP with high psychiatric severity are not characterized by a lower retention in treatment or higher substance use than those with low psychiatric severity. Moreover, during treatment high severe psychiatric patient status appears to improve significantly for all psychological/psychiatric dimensions explored by SCL-90. These results are consistent with those obtained in previous studies on the efficacy of MMTP, comprehensive of psychiatric care, irrespective of the severity of psychopathology exhibited by patients at the beginning of treatment.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21178355     DOI: 10.1159/000321465

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  14 in total

1.  Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment.

Authors:  Jonathan D Savant; Declan T Barry; Christopher J Cutter; Michelle T Joy; An Dinh; Richard S Schottenfeld; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2012-07-06       Impact factor: 4.492

2.  Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder.

Authors:  Margaret L Griffin; Dorian R Dodd; Jennifer S Potter; Lindsay S Rice; William Dickinson; Steven Sparenborg; Roger D Weiss
Journal:  Am J Drug Alcohol Abuse       Date:  2013-11-12       Impact factor: 3.829

3.  The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a U.S. national sample.

Authors:  Noa Krawczyk; Kenneth A Feder; Brendan Saloner; Rosa M Crum; Marc Kealhofer; Ramin Mojtabai
Journal:  Drug Alcohol Depend       Date:  2017-04-19       Impact factor: 4.492

4.  Experience of social discrimination correlates with neurometabolism: a pilot study in heroin addicts.

Authors:  Ulrich Frischknecht; Derik Hermann; Milena Heinrich; Mareen Hoerst; Wolfgang Weber-Fahr; Sabine Vollstädt-Klein; Falk Kiefer; Karl Mann; Gabriele Ende
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-05-09       Impact factor: 5.270

5.  Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.

Authors:  Joanna M Streck; Taylor A Ochalek; Gary J Badger; Stacey C Sigmon
Journal:  Exp Clin Psychopharmacol       Date:  2018-06-25       Impact factor: 3.157

6.  Changes in secondary outcomes associated with brief interventions for problem gambling in methadone patients.

Authors:  Catherine Baxley; Jeremiah Weinstock; Carla J Rash; Matthew M Yalch; Brian Borsari; Annie A Garner; Jeffrey Benware
Journal:  Addict Behav       Date:  2021-04-20       Impact factor: 4.591

7.  Comorbid Psychopathology and Alcohol Use Patterns among Methadone Maintenance Treatment Patients.

Authors:  Georgios Moussas; Irene Fanouraki; Argiro Pachi; Arezina Asomatou; Olga Drylli; Georgios Paschalakis; Athanasios Tselebis; Konstantinos Giotakis; Dionisios Bratis; Georgios Dermatis; Meni Malliori
Journal:  J Addict       Date:  2015-03-23

Review 8.  New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.

Authors:  Michael Soyka
Journal:  Subst Abuse Rehabil       Date:  2015-01-06

9.  Correlates of Nine-Month Retention following Interim Buprenorphine-Naloxone Treatment in Opioid Dependence: A Pilot Study.

Authors:  A Håkansson; C Widinghoff; T Abrahamsson; C Gedeon
Journal:  J Addict       Date:  2016-01-21

10.  The impact of psychopathological subtypes on retention rate of patients with substance use disorder entering residential therapeutic community treatment.

Authors:  Angelo G I Maremmani; Pier Paolo Pani; Emanuela Trogu; Federica Vigna-Taglianti; Federica Mathis; Roberto Diecidue; Ursula Kirchmayer; Laura Amato; Joli Ghibaudi; Antonella Camposeragna; Alessio Saponaro; Marina Davoli; Fabrizio Faggiano; Icro Maremmani
Journal:  Ann Gen Psychiatry       Date:  2016-11-08       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.